Page last updated: 2024-08-21

pyrazines and Chloroma

pyrazines has been researched along with Chloroma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Kim, RS; Shields, CL; Wilde, LR; Yaghy, A1
Baughn, LB; Janz, S; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F1
Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W1
Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P1

Trials

1 trial(s) available for pyrazines and Chloroma

ArticleYear
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Sarcoma, Myeloid; Survival Rate; Thalidomide

2012

Other Studies

3 other study(ies) available for pyrazines and Chloroma

ArticleYear
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
    JAMA ophthalmology, 2020, 04-01, Volume: 138, Issue:4

    Topics: Administration, Oral; Aniline Compounds; Ciliary Body; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Uveal Neoplasms; Visual Acuity

2020
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Multiple Myeloma; Prognosis; Pyrazines; Receptors, CXCR4; Sarcoma, Myeloid; Survival Rate

2013
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
    American journal of hematology, 2015, Volume: 90, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis

2015